2026
- We received the regulatory clearance from the NMPA for conducting and launched a Phase III clinical trial of XTR008 for advanced SSTR-positive G3 GEP-NETs/PPGLs/NENs of other origins.
2025
- We completed Jan-2025 Capital Increase and raised approximately RMB200 million.
- We commenced the commercialization and launched XTR005 (歐韋寧®) in hospitals across China, achieving GMP-standardized production and commercialization.
2024
- We were awarded the national “Specialized, Refined, and New ‘Little Giant’” (国家级专精特新“小巨人”企业) enterprise title.
- Jiangsu Sinotau Pharmaceutical obtained the Radiopharmaceutical Business License (放射性药品经营许可证).
- We completed the Nov-2024 Capital Increase and raised approximately RMB400 million.
2023
- We completed Jun-2023 Capital Increase and raised approximately RMB1,100 million.
- We received regulatory approval from NMPA for XTR005 (欧韦宁®).
- Glotope commenced radiopharmaceutical CRO/CDMO business.
2022
- We obtained clinical trial approval for XTR008.
2021
- Shanghai Sinotau was established.
2020
- We obtained clinical trial approvals for XTR004.
2019
- We obtained clinical trial approval of XTR005 (欧韦宁®), the first
radiopharmaceutical clinical trial approval we obtained .
- We completed the Division and focusing on the radiopharmaceutical market.
2018
- We voluntarily delisted from the NEEQ.
2014
- Started the research and development of radiopharmaceutical.
2005
- Our Company was established.
